693 related articles for article (PubMed ID: 29549527)
1. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
2. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
4. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
Forde K; Resta N; Ranieri C; Rea D; Kubassova O; Hinton M; Andrews KA; Semple R; Irvine AD; Dvorakova V
Orphanet J Rare Dis; 2021 Feb; 16(1):109. PubMed ID: 33639990
[TBL] [Abstract][Full Text] [Related]
6.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
7. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
9. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
10. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
[TBL] [Abstract][Full Text] [Related]
11. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
12. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
[TBL] [Abstract][Full Text] [Related]
13. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation.
Da Costa R; De Almeida S; Chevarin M; Hadj-Rabia S; Leclerc-Mercier S; Thauvin-Robinet C; Garrido C; Faivre L; Vabres P; Duplomb L; Jego G
Biochem Biophys Res Commun; 2020 Sep; 530(3):520-526. PubMed ID: 32620236
[TBL] [Abstract][Full Text] [Related]
16. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
Blesinger H; Kaulfuß S; Aung T; Schwoch S; Prantl L; Rößler J; Wilting J; Becker J
PLoS One; 2018; 13(7):e0200343. PubMed ID: 29985963
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
19. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
